Today's Rundown Novo bags €430M Staten buyout option to boost cardiovascular disease pipeline Innovent buys Chinese rights to Incyte drugs for $40M upfront Bristol-Myers, H3 Biomedicine explore RNA splicing drugs for cancer [Sponsored] Six Practices of High Performing Clinical Research Sites Imugene ‘encouraged’ by data for HER2 vaccine in gastric cancer Versant closes two new biotech funds totaling $700M As promised, Novartis eyes new method for funding ultrapricey next-gen drugs: FT Featured Story | | | Monday, December 17, 2018 Novo Nordisk has landed an option to buy Staten Biotechnology in a €430 million deal. The agreement gives Novo the chance to add an anti-apoC3 antibody treatment for abnormal lipid levels to its pipeline. |
|
|
| This week's sponsor is FierceBiotech. | | | |
Top Stories Monday, December 17, 2018 Innovent Biologics has bagged the Chinese rights to three clinical-phase oncology and hematology drugs in development at Incyte. The agreement sees Innovent pay $40 million upfront and commit to about $350 million in milestones for a trio of drugs that are in phase 2 and 3 testing in the West. Monday, December 17, 2018 Bristol-Myers Squibb is tapping Eisai spinoff H3 Biomedicine and its RNA-splicing technology for a multiyear research partnership. The pair will investigate whether new treatments based on H3’s platform can elicit a stronger response against cancer. Monday, December 17, 2018 Clinical research sites have a tough, but critically important, job. It’s rigorous and precise work, but essential to the progress of medicine. Monday, December 17, 2018 Australian biotech Imugene says its HER2 vaccine hit the mark in a phase 1b trial, setting up a phase 2 study that will start recruiting patients in the new year. Monday, December 17, 2018 Versant Ventures unveiled a pair of new funds—a $600 million global biotech fund, its seventh, and a $100 million companion fund that will focus on startups in Canada. The new funds, dubbed Versant Venture Capital VII and Versant Voyageurs I, come nearly two years after the VC firm reeled in a $400 million fund. Monday, December 17, 2018 Novartis is weighing an insurance method often associated with natural disasters to help win coverage for its pricey next-generation cell and gene therapies. Reinsurance would underwrite a different sort of catastrophe, Novartis CEO Vas Narasimhan told the Financial Times. Resources Sponsored by: DocuSign Life sciences companies must immediately identify and realize productivity gains to drive down operational costs—or risk seeing more nimble competitors disappear into the distance. Where to begin? Sponsored by: Veeva Learn how to spot an imposter with an integrated suite vs. one that’s unified. Read this whitepaper to learn more. Sponsored by: Patheon, part of Thermo Fisher Scientific Read this whitepaper to learn how the biologics market is quickly evolving and how these changes pose several risks to a molecule’s success. Sponsored by: Coupa Software Learn how Becton Dickinson implemented Coupa to create an easy-to-use purchase to pay process that increased efficiency across the organization. Sponsored by: Almac Diagnostic Services, part of the Almac Group Download the whitepaper to learn more. Sponsored by: Reprints Desk, Inc. Learn how to fast-track your research workflows! Sponsored by: Veeva Industry Research: Read the 2018 Unified Clinical Operations Report to find out how pharmas and CROs are evolving clinical trial processes. Sponsored by: Applied BioMath This on-demand webinar introduces a quantitative systems pharmacology (QSP) model of targeted anabolic growth factors for intra-articular injection for the treatment of diseased joints. Sponsored by: Oracle Health Sciences New research reveals more than 50% of clinical data management professionals surveyed, are not confident in the quality and completeness of their clinical trial data. Sponsored by: Outer Edge Technology Outer Edge Technology specializes in designing and managing regulated cloud-based infrastructures for the Life Sciences Industry – typically leveraging the AWS and Microsoft Azure platforms. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. Drug Approval, Manufacturing Quality & Regulation 2018 | Online FierceBiotech Executive Breakfast at the J.P. Morgan Healthcare Conference 2019 January 8, 2019 | The Fairmont Hotel | San Francisco, CA Phacilitate Leaders World 2019 January 22-25, 2019 I Hyatt Regency, Miami Asia-Pacific Compliance Training for Life Sciences Professionals March 4-7, 2019 | Singapore 2019 Bridging Clinical Research & Clinical Health Care Collaborative March 4–5, 2019 | National Academy of Sciences | Washington, D.C. PEGS: The Essential Protein Engineering Summit April 8 – 12 | Boston, MA | 